Cosentyx vs Taltz

Cosentyx and Taltz are both IL-17A inhibitors reviewed for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. Cosentyx is also indicated for active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, and moderate to severe hidradenitis suppurativa.

In its pivotal trials, Cosentyx demonstrated a PASI 75 response of 95% and 83% in different assessments, and an IGA of clear or almost clear in 65% and 62% of patients. Taltz, in its own trials, showed statistical superiority to placebo for primary and key secondary efficacy endpoints with p-values < 0.001, and a PASI-75 response rate of 90%. It also reported an sPGA (0,1) response rate of 83%.

It is crucial to note that these drugs were studied in separate trials with different designs, patient populations, endpoints, and timepoints. The figures presented are from each drug's own regulatory review documents and are not head-to-head comparisons. Therefore, neither drug is presented as superior to the other based on these figures.